Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300
Open Access
- 29 July 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (8) , 3094-3103
Abstract
The transcriptional coactivators EP300 and CREBBP are critical regulators of gene expression that share high sequence identity but exhibit nonredundant functions in basal and pathological contexts. Here, we report the development of a bifunctional small molecule, MC-1, capable of selectively degrading EP300 over CREBBP. Using a potent aminopyridine-based inhibitor of the EP300/CREBBP catalytic domain in combination with a VHL ligand, we demonstrate that MC-1 preferentially degrades EP300 in a proteasome-dependent manner. Mechanistic studies reveal that selective degradation cannot be predicted solely by target engagement or ternary complex formation, suggesting additional factors govern paralogue-specific degradation. MC-1 inhibits cell proliferation in a subset of cancer cell lines and provides a new tool to investigate the noncatalytic functions of EP300 and CREBBP. Our findings expand the repertoire of EP300/CREBBP-targeting chemical probes and offer insights into the determinants of selective degradation of highly homologous proteins.Keywords
All Related Versions
Funding Information
- McGill University
- Kungliga Tekniska H?gskolan
- Diamond Light Source
- Innovative Medicines Initiative (875510)
- Center for Cancer Research (BC011488)
- Horizon 2020 Framework Programme
- European Federation of Pharmaceutical Industries and Associations
- Ontario Institute for Cancer Research
This publication has 39 references indexed in Scilit:
- Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor ActivityJournal of Medicinal Chemistry, 2024
- Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerJournal of Medicinal Chemistry, 2024
- Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionJournal of Medicinal Chemistry, 2024
- Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 ProteinsJournal of Medicinal Chemistry, 2023
- KATs off: Biomedical insights from lysine acetyltransferase inhibitorsCurrent Opinion in Chemical Biology, 2022
- Targeted degradation of the enhancer lysine acetyltransferases CBP and p300Cell Chemical Biology, 2021
- Compartmentalised acyl-CoA metabolism and roles in chromatin regulationMolecular Metabolism, 2020
- Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical DegraderCell Chemical Biology, 2020
- Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AMLCell Chemical Biology, 2019
- Global and Specific Responses of the Histone Acetylome to Systematic PerturbationMolecular Cell, 2015